Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study

PURPOSE: In the multinational, randomized, double-blind, Phase 3 B2305 study of patients with Cushing’s disease (CD; ClinicalTrials.gov identifier NCT00434148), pasireotide substantially decreased urinary-free cortisol (UFC) levels, decreased mean corticotroph tumor volume, and improved clinical sig...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pituitary
Hlavní autoři: Lacroix, André, Gu, Feng, Schopohl, Jochen, Kandra, Albert, Pedroncelli, Alberto M., Jin, Lixian, Pivonello, Rosario
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7181422/
https://ncbi.nlm.nih.gov/pubmed/31875276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11102-019-01021-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky